This inventor holds 35 USPTO granted patents and 21 published patent applications, plus 3 CIPO patents and 12 EPO patents, primarily in Ocular Drug Delivery. Top assignees: Glaukos Corporation, Dose Medical Corporation, Edwards Lifesciences Corporation. Active years: 1990-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Mission Veijo, CA (US) (1990)
- South Jordan, UT (US) (2012 - 2016)
- San Clemente, CA (US) (2020)
- Oceanside, CA (US) (1994 - 2023)
Company Filing History:
11 out of 121 
10 out of 19 
6 out of 1,791 
Years Active: 1990-2026
Areas of Expertise:
Title: Kenneth Martin Curry: Innovator in Ocular Drug Delivery
Introduction: Kenneth Martin Curry, based in Oceanside, California, is a prominent inventor recognized for his contributions to the field of ocular drug delivery. With an impressive portfolio consisting of 22 patents, Curry has dedicated his career to developing innovative solutions for treating ocular disorders, significantly improving patient outcomes.
Latest Patents: Among his latest breakthroughs are two notable patents focusing on drug delivery mechanisms designed for ocular treatment. The first patent, titled "Implants with Controlled Drug Delivery Features and Methods of Using Same," discloses devices and methods that enable targeted and controlled administration of drugs to the interior portion of the eye. These devices are crucial for reducing or preventing symptoms of ocular disorders and include features that address increased intraocular pressure by allowing aqueous humor to flow out of the anterior chamber. The second patent, "Drug Eluting Ocular Implant and Method of Treating an Ocular Disorder," echoes these advancements and further emphasizes the importance of controlled drug release in the field.
Career Highlights: Throughout his career, Kenneth Martin Curry has collaborated with notable companies, including Dose Medical Corporation and Edwards Lifesciences Corporation. His work with these organizations has paved the way for the development of groundbreaking technologies aimed at improving ocular health.
Collaborations: Alongside reputable colleagues such as David S. Haffner and Harold Alexander Heitzmann, Curry has fostered an environment of innovation. Their combined efforts in research and development have played a significant role in advancing ocular drug delivery systems.
Conclusion: Kenneth Martin Curry exemplifies the spirit of innovation in the medical device industry, particularly in the realm of ocular treatments. His dedication to research and development is evident through his impressive patent portfolio and collaborations, ultimately contributing to improved solutions for those suffering from ocular disorders.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile